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Background: Radiation-induced rib fracture after stereotactic body radiotherapy (SBRT) for lung cancer has been
recently reported. However, incidence of radiation-induced rib fracture after SBRT using moderate fraction sizes with
a long-term follow-up time are not clarified. We examined incidence and risk factors of radiation-induced rib
fracture after SBRT using moderate fraction sizes for the patients with peripherally located lung tumor.
Methods: During 2003–2008, 41 patients with 42 lung tumors were treated with SBRT to 54–56 Gy in 9–7 fractions.
The endpoint in the study was radiation-induced rib fracture detected by CT scan after the treatment. All ribs where
the irradiated doses were more than 80% of prescribed dose were selected and contoured to build the dose-volume
histograms (DVHs). Comparisons of the several factors obtained from the DVHs and the probabilities of rib fracture
calculated by Kaplan-Meier method were performed in the study.
Results: Median follow-up time was 68 months. Among 75 contoured ribs, 23 rib fractures were observed in 34% of
the patients during 16–48 months after SBRT, however, no patients complained of chest wall pain. The 4-year
probabilities of rib fracture for maximum dose of ribs (Dmax) more than and less than 54 Gy were 47.7% and 12.9%
(p = 0.0184), and for fraction size of 6, 7 and 8 Gy were 19.5%, 31.2% and 55.7% (p = 0.0458), respectively. Other factors,
such as D2cc, mean dose of ribs, V10–55, age, sex, and planning target volume were not significantly different.
Conclusions: The doses and fractionations used in this study resulted in no clinically significant rib fractures for this
population, but that higher Dmax and dose per fraction treatments resulted in an increase in asymptomatic grade 1 rib
fractures.
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Table 1 Patients and tumor characteristics
Patients (n = 41)
Age (y), mean and range 75 (45–86)
Sex (Male/Female) 29/12
Diagnosis
Lung cancer (cT1N0M0) 28
Lung cancer (cT2N0M0) 5
Lung metastasis 9
Performance status (0/1/2) 23/16/2
Tumors (n = 42)
Location (upper/middle/lower) 28/1/13
Location (anterior/lateral/posterior) 7/19/16
GTV (cm3), mean and range 7.6 (1–31)
PTV (cm3), mean and range 44.0 (11–134)
Abbreviations: GTV = gross tumor volume; PTV = planning target volume.
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Stereotactic body radiotherapy (SBRT) has been widely
used for patients with inoperable primary and metastatic
lung tumor. Historically, numerous clinical trials of
SBRT for lung tumor with excellent primary control
without severe toxicities have been reported [1-9]. Re-
cently, however, frequencies of radiation-induced rib
fracture, especially with peripherally located lung tumor
treated with SBRT [10-12], have clearly become unex-
pectedly high compared to other methods of radiother-
apy, such as tangential breast irradiation of breast
conserving therapy [13].
Radiation-induced rib fracture is recognized as a late
toxicity after external beam radiotherapy to the chest wall.
From the radiobiological standpoint, larger fraction size is
likely to increase the frequency of radiation-induced rib
fracture [14]. However, fraction size for SBRT is relatively
large; we have therefore started SBRT with moderate frac-
tion size of 6 Gy since 2003 in order to avoid late toxicities
and previously published our initial clinical experience of
SBRT for lung tumors using 54 Gy in 9 fractions [15]. We
have also started a dose escalation study of the fraction
size by 1 Gy each from 6 Gy. However, some of the pa-
tients treated this way have developed rib fractures after
SBRT. The purpose of this study is to investigate
radiation-induced rib fracture, looking at incidence and
risk factors for the patients with peripheral lung tumor
treated with SBRT using moderate fraction sizes.
Methods
This study was approved by the ethics committee of
Hirosaki university school of medicine, and written
informed consent was obtained from all patients.
Patient and tumor characteristics
Between May 2003 and August 2008, 61 patients with
medically inoperable lung tumor were treated with SBRT
to 54–56 Gy in 9–7 fractions. The inclusion criteria for
the current study were at least 15 months of radio-
graphic follow-up, the tumor located within 2 cm of the
chest wall, and patients with less than 10 mm of respira-
tory motion. Among the 61 patients, there were 6 pa-
tients excluded due to short follow-up time less than
15 months and 14 patients excluded due to tumor loca-
tion. Therefore the subjects of this study included 41 pa-
tients (28 Stage IA lung cancers, 5 Stage IB lung cancers
and 9 lung metastases). Among the 41 patients, one had
two lung metastases, so 42 tumors were analyzed in this
study. The patients and tumor characteristics are sum-
marized in Table 1.
Treatment procedure
All patients had raised both upper arms and were immo-
bilized by a thermo-shell (ALCARE Co., Ltd., Tokyo,Japan) and a custom-made headrest using MoldCare
(ALCARE Co., Ltd., Tokyo, Japan) during the treatment.
After patient immobilization, respiratory movement of
the tumor that was no more than 10 mm was confirmed
with X-ray simulator (Toshiba Medical Systems Co., Ltd.,
Tokyo, Japan). Computed tomography (CT) was taken with-
out breath holding by a CT-simulator (Aquilion, Toshiba
Medical Systems Co., Ltd., Tokyo, Japan) with 2.0 mm
thickness to recognize tumor localization and for dose cal-
culation. A three-dimensional (3D) radiotherapy treatment-
planning (RTP) machine (XiO, ver4.1.1, CMS Japan, Tokyo,
Japan) was applied for the dose calculation. The outline of a
target and normal tissues (total lung, spinal cord, vertebrae
and or bronchus) were made for all patients. The target
margins were defined as follows: clinical target volume
(CTV) was equal to gross tumor volume (GTV); internal
target volume (ITV) was CTV plus 5–10 mm margin
according to respiratory movement of tumors confirmed
with X-ray simulator; planning target volume (PTV) was
CTV plus 5 mm margin in all directions according to set-
up accuracy. A leaf margin was also taken 5 mm around
the PTV. The patients in this study were treated before
the introduction of 4D CT in our institution.
The dose calculation for the treatment was performed
with Clarkson method by 3D-RTP corrected for in-
homogeneity. The treatment was conducted on 42 lung
tumors by fixed multiple non-coplanar conformal beams
by a 10-MV standard linear accelerator with EXL-20TP
(Mitsubishi Electric Co., Ltd., Tokyo, Japan). The beam
arrangement consisted of 3 non-coplanar oblique anter-
ior beams plus 2 coplanar oblique posterior beams plus
1 coplanar lateral beam.
Among the 41 patients meeting the inclusion criteria,
fractionation schedules of SBRT were administered as
(B)
(A)
Figure 1 An 83-year-old woman with adenocarcinoma after SBRT
with a total dose of 56 Gy given in 7 fractions. (A): Dosimetry
overlaying CT with bone window shows the 95% iso-dose line on
the right 5th rib. (B): Rib fracture was noted at 36 months after
SBRT (arrow).
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56 Gy given in 8 fractions for next 13 patients; 56 Gy
given in 7 fractions for last 14 patients. The prescribed
dose was defined at isocenter. The mean value of hot
spots in the PTV was 56.26 Gy (range, 54.1–58.8 Gy).
The hot spot in the PTV was within +5% of the iso-
centric dose (mean: 1.854%, range: 0.31 - 4.96%). The
median overall treatment time was 12 days and ranged
9–22 days. The localization of the tumor was confirmed
before every treatment by an electronic portal-imaging
device (EPID), and EPID-based setup was performed on
bony anatomy in this study.
Contouring and dose-volume histograms
For the 41 patients meeting the inclusion criteria, all ribs
where the irradiated doses were more than 80% of pre-
scribed dose were contoured without margin for set-up
movements. The dose calculation for the evaluation of
radiation-induced rib fracture was performed with
Clarkson method corrected for inhomogeneity. Each cu-
mulative dose-volume histogram (cDVH) was exported
to a file using a dose bin size of 0.2 Gy. The parameters
of rib volume receiving 10–55 Gy (V10–55), dose at 2 cc
of rib (D2cc), maximum dose of rib (Dmax), mean dose
of rib (Dmean) and planning target volume (PTV) were
analyzed using cDVHs. The dose calculation grid size
for cDVHs was 3 mm, and the volume to define parame-
ters of cDVHs was the whole scanning area including
whole ribs in the study.
Follow-up and statistics
The endpoint in the current study was radiation-
induced rib fracture, detected by CT scan at any time
after the treatment; rib fractures according to tumor in-
vasion were excluded in the current study. The end
point was defined for each rib. Follow-up CT scans were
obtained at 3–6 month intervals and were used to assess
toxicity (Figure 1). All available CT scans were checked
for rib fracture, not only of selected ribs but also excluded
ribs. Toxicities were assessed according to the Common
Terminology Criteria for Adverse Events Version 3.0
(CTCAE v3.0). The patients were also periodically moni-
tored by medical examinations after the treatment.
All statistical analyses were performed with a commer-
cial statistical software package (Dr. SPSS II for Windows,
Version 11.0.1 J, SPSS Inc., Tokyo). The statistical signifi-
cance of differences in mean values (V10–55, D2cc, Dmax,
Dmean, and PTV) between two populations obtained by
cDVHs was assessed with Student’s t-test. The actuarial
curve was calculated with Kaplan-Meier method, accord-
ing to the interval from the first date of the treatment, and
differences in their distributions were evaluated using the
log–rank test. Prognostic factors included in the analyses
were age (≧75 vs. <75), sex (male vs. female), Dmax(≧54 Gy vs. < 54Gy), fraction size (6 Gy vs. 7 Gy vs. 8 Gy),
PTV (≧50 cc vs. < 50 cc), tumor location (anterior vs. pos-
terior vs. lateral: divided into three equal parts of the
lung), rib location (1–4 vs. 5–8 vs. 9–12). Differences were
regarded as statistically significant at p < 0.05.
Results
Incidence of radiation-induced rib fracture
Median follow-up time was 68 months, and ranged 16–
130 months. For the 41 patients meeting the inclusion
criteria, a total of 75 ribs were contoured. Among the 75
contoured ribs, 23 rib fractures were noted in 34% (14/41)
of the patients during 16–48 months (median 30 months)
after SBRT. No rib fracture was observed on excluded ribs
in any patient in the study. Among the 14 patients with
rib fractures, no one complained of chest wall pain, and
(C) DVHs with standard deviation
(B) Without rib fracture (n = 52)
(A) With rib fracture (n = 23)
Figure 2 All cumulative DVHs for ribs. DVHs with fracture (A), without fracture (B), and DVHs with standard deviation (C) with fracture (solid
curve) and without fracture (dotted curve).
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fracture for the study patients was judged to be Grade1 ac-
cording to CTCAE v3.0. Also, the remaining 27 patients
without rib fractures, never complained of chest wall pain.Dose volume histogram
The mean volume of the 75 contoured ribs was
22.5 cm3 (range: 6.0–39.5 cm3). The group with rib frac-
ture had slightly larger volumes of the high dose level
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rib fracture on cDVHs. The cDVHs are shown in
Figure 2.
The mean values of the variables (V10–55, D2cc, Dmax,
Dmean, and PTV) according to with or without rib fracture
are listed on Table 2. Only Dmax was a significant factor
for the radiation-induced rib fracture (p = 0.012), whereas
V10–55, D2cc, Dmean, and PTV were not significant.
Probability of the radiation-induced rib fracture
Dmax of the rib and fraction size were significant factors
for rib fracture on univariate analysis. The probability of
the radiation-induced rib fracture at 4 years according to
the Dmax of the rib less than and more than 54 Gy were
12.9% and 47.7%, respectively (p = 0.0184), which is
shown in Figure 3A. The probability of the radiation-
induced rib fracture at 4 years according to the fraction
size of 6, 7 and 8 Gy were 19.5%, 31.2% and 55.7%, re-
spectively (p = 0.0458), which is shown in Figure 3B.
Other factors, such as age, sex, PTV, tumor and rib loca-
tion were not significant on univariate analysis, which
are summarized in Table 3.
No radiation-induced rib fracture was observed in the
cases of fraction size with 6, 7, and 8 Gy for the value of
Dmax of the ribs less than 53.6 Gy, 53.4 Gy, and
54.2 Gy, respectively. A cutoff value of the radiation-
induced rib fracture for the Dmax of the rib was ap-
proximately 53 Gy, however, average values of Dmax
with rib fracture were somehow related to the fraction
size. They were 54.7, 55.5 and 56.1 Gy for 6, 7 and
8 Gy, respectively. Calculated biologically effective dose
(BED8, α/β is assumed to be 8 Gy reported by Nambu
et al. [16]) for the average values of Dmax in the patientsTable 2 Summary of mean values for categories with and
without rib fracture
Categories With fracture, n = 23 Without fracture, n = 52 p value
Mean value (range) Mean value (range)
V10 (cc) 10.8 (4.4–18.6) 11.8 (3.0–28.7) 0.413
V20 (cc) 7.3 (3.4–11.6) 8.5 (1.7 - 18.2) 0.130
V30 (cc) 5.5 (2.7–9.1) 6.3 (1.1 - 15.1) 0.200
V40 (cc) 4.2 (1.9–7.9) 4.6 (0.6 - 11.7) 0.442
V50 (cc) 2.5 (0.3–6.7) 2.2 (0.0 - 8.0) 0.493
V53 (cc) 1.7 (0.01–6.0) 1.1 (0–5.0) 0.092
V54 (cc) 1.4 (0–5.6) 0.7 (0–4.5) 0.099
V55 (cc) 1.0 (0–4.8) 0.4 (0–3.6) 0.093
D2cc (Gy) 49.7 (38.6–56.8) 47.8 (16.7–56.4) 0.276
Dmax (Gy) 55.7 (53.4–58.4) 54.7 (50.1–58.8) 0.012
Dmean (Gy) 18.4 (12.6–33.7) 17.8 (11.1–29.2) 0.598
PTV (cc) 53.7 (14.8–133.7) 50.5 (13.8–133.7) 0.672
Abbreviations: Dmax =maximum dose of ribs; Dmean =mean dose of ribs;
PTV = planning target volume.with rib fracture, were 96.3, 103.6 and 112.3 Gy for the
fraction size of 6, 7 and 8 Gy, respectively.
Discussion
Radiation-induced rib fracture is one of the late radi-
ation injuries not only for the patients with breast cancer
treated with conventional postoperative radiotherapy but
also for the patients with lung tumor treated with
stereotactic body radiotherapy (SBRT). In our study,
radiation-induced rib fracture was noted in 34% of the
patients (14/41) during 16–48 months after SBRT. The
incidence of rib fracture was significantly dependent
upon Dmax and fraction size. The probability of the
radiation-induced rib fracture at 4 years was approxi-
mately 50% for the Dmax more than 54 Gy and the frac-
tion size of 8 Gy. The incidence of radiation-induced rib
fracture was relatively high; however, no patients com-
plained of chest wall pain and no rib fracture was noted
for the rib with the Dmax less than 53 Gy.
The development of radiation-induced rib fracture
with external beam radiotherapy is well documented.
The incidence of radiation-induced rib fracture was 0.3–
6% for patients with breast cancer. A retrospective ana-
lysis by Overgaard [14] examined the incidence of
radiation-induced rib fracture detected by follow-up
chest radiographs in 231 breast cancer patients treated
with post mastectomy irradiation. The incidence of rib
fracture was reported to be 19% for a large fraction size
and 6% for a standard fraction size. Pierce et al. [13]
reviewed 1,624 patients with early stage breast cancer
treated by breast conserving therapy and reported the
incidence of symptomatic rib fracture with or without x-
ray confirmation to be 0.4–2.2%. A similar incidence of
radiation-induced rib fracture detected by follow-up
chest radiographs or CT has been reported in patients
with non-small cell lung cancer treated with palliative
radiotherapy by Quddus et al. [17].
When comparing these series with the literature re-
garding initial studies of SBRT, however, the incidence
of radiation-induced pulmonary toxicity is well docu-
mented but the precise incidence of radiation-induced
rib fracture is unknown. Uematsu et al. [1] reported a
5-year experience of SBRT using 50–60 Gy in 5–10 frac-
tions with a median follow-up of 36 months for 50 pa-
tients, and reported that only one patient (2%) had a rib
fracture detected by follow-up CT without requiring
medical treatment. Onishi et al. [2] reported a clinical
outcome in 245 subjects in a Japanese multi-institutional
study of SBRT for stage I non-small cell lung cancer, and
the incidence of rib fracture detected by follow-up CT
was reported to be only 0.8% with a median follow-up of
24 months. In other early reports of SBRT, radiation-
induced rib fracture has not been well documented, be-
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8 Gy (n = 27)
7 Gy (n = 23)
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p = 0.0458
Figure 3 Cumulative incidence of radiation-induced rib fracture. Dmax more than and less than 54 Gy (A), fraction size of 6, 7, and 8 Gy (B).
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hand, several recent studies of SBRT concerning radiation-
induced rib fracture have been reported. Zimmermann
et al. [7] reviewed 30 patients with stage I non-small cell
lung cancer treated by SBRT with a total dose ranged from
24 to 37.5 Gy given in 3–5 fractions to the 60% isodose
encompassing the planning target volume, and the inci-
dence of rib fracture detected by follow-up CT wasreported to be 3%. Similar incidence of radiation-induced
rib fracture detected by follow-up CT with or without chest
wall pain has been reported by Nyman et al. [8], and Fritz
et al. [9].
However, incidence of rib fracture rises dramatically
when treating lesions that are close to the chest wall.
Voroney et al. [10] reported a series of 42 peripherally
located lung lesions treated by SBRT with a total dose of
Table 3 Probabilities of radiation-induced rib fracture
(n = 75)
Categories n 4y-rates (%) p values
Age (y)
≧75 47 37.5 NS
<75 28 40.0
Sex
Male 50 32.7 NS
Female 25 47.2
Dmax (Gy)
≧54 55 47.7 0.0184
<54 20 12.9
Fraction size (Gy)




≧50 28 41.2 NS
<50 47 35.5
Tumor location




1–4 40 31.0 0.0738
5–8 35 42.1
9–12 6 75.0
Abbreviations: Dmax =maximum dose of ribs; PTV = planning target volume;
NS = not significant; HR = hazard ratio; CI = confidence interval.
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was reported to be 21% (n = 9) with a median time to
occurrence of 17 months, and rib fractures were symp-
tomatic in 7 patients, whereas asymptomatic in 2
patients. Similar incidence of 16–24% for radiation-
induced rib fracture detected by follow-up CT with or
without chest wall pain after SBRT, and risk factors of
dose and irradiated volume for the rib were reported by
Pettersson et al. [11], Andolino et al. [12], and Asai
et al. [18]. In addition, tumor location and patients’ fac-
tor are also associated with radiation-induced rib frac-
ture. Nambu et al. [16] reported prevalence, degree of
clinical symptoms, and risk factors for rib fracture de-
tected by follow-up CT after SBRT with 177 patients,
and found that small tumor-chest wall distance and fe-
male sex are risk factors for rib fracture. Kim et al. [19]
reported risk factors for rib fracture detected by follow-
up CT after SBRT with 118 patients with 2 year rib
fracture rate of 42.4%, and concluded that female gen-
der and lateral tumor location are risk factors for ribfracture. In this way, several factors associated with rib
fracture must be considered, including dose, volume
and site of irradiated rib, and patients’ characteristics.
Further, the incidence of symptomatic rib fracture or
asymptomatic rib fracture is also important issue.
Nambu et al. [20] well discussed the incidence of rib
fracture and chest wall pain for 177 primary lung can-
cer patients after SBRT. The incidence of symptomatic
rib fracture, asymptomatic rib fracture, and chest wall
pain without rib fracture were reported to be 7.9%,
15.3%, and 2.3%, respectively. In other words, the per-
centage of symptomatic rib fractures was 34.1% in their
study with a total dose of 48–70 Gy in 4–10 fractions.
Asai et al. [19] reported larger percentage of symptom-
atic rib fracture after SBRT with a total dose of 48 Gy
in 4 fractions, and was 42.9%. On the other hand, no
symptomatic rib fractures were observed in our study.
Moderate fraction size of 6–8 Gy might be minimized
symptomatic rib fracture.
In our study, even though moderate fraction size of
6–8 Gy used, radiation-induced rib fracture occur, and
rib fracture is strongly correlated with Dmax and frac-
tion size. The difference of the values of Dmax is only
1 Gy when comparing the Dmax with the DVH
(Table 2), but a big difference is observed when com-
paring probability of rib fracture with Kaplan-Meier
method (Figure 3A). The fraction size also had signifi-
cant impact on the incidence of radiation-induced rib
fracture. When comparing the fraction size with the
same total dose (56 Gy per 8 fractions vs. 56 Gy per 7
fractions; for which fraction sizes were 7 Gy and 8 Gy,
respectively), the probability of rib fracture according
to the fraction size are significantly different, as shown
in Figure 3B.
Based on these results, while normal tissue doses
should always be minimized, it is not important to sup-
press rib dose within the range of doses used in this
study. In addition, long-term follow-up is also neces-
sary for the evaluation of radiation induced late bone
damage, because the radiation-induced rib fractures oc-
curred at 48 months after SBRT in our series. With a
median follow-up period of 68 months in our series,
fracture rate of 34% is higher than the crude rates of
3–5% quoted from initial studies of SBRT [7-9], but
similar with recent studies for peripheral lung tumor
[10-12,16,18,19]. Although the incidence of radiation-
induced rib fracture is high, it does not necessarily re-
quire change in the treatment plan and/or prescribed
dose, because the 14 patients with rib fracture did not
complain of chest wall pain and the rib fracture healed
without treatment. However, there is a report that
obesity increases the risk of chest wall pain from SBRT
[21,22], so it is necessary to pay attention in such
patients.
Aoki et al. Radiation Oncology  (2015) 10:99 Page 8 of 8Conclusion
In conclusion, the doses and fractionations used in this
study resulted in no clinically significant rib fractures for
this population, but that higher Dmax and dose per frac-
tion treatments resulted in an increase in asymptomatic
grade 1 rib fractures.
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